Merck KGaA Gets U.S. Patents for Genome-Editing Technology
May 11 2020 - 10:00AM
Dow Jones News
By Olivia Bugault
Merck KGaA said Monday that two of its CRISPR-Cas9-assisted
genome-editing patents have been granted in the U.S.
The pharmaceutical company is in talks to license its technology
that will support scientists and researchers in the development of
therapies for difficult-to-treat diseases, it said. The two patents
have been granted for its CRISPR-Cas9 cleavage and integration
technology.
"The company has CRISPR patents granted in Australia, Canada,
China, Europe, Israel, Singapore and South Korea with related
patent filings in Brazil, India and Japan," Merck KGaA said.
CRISPR-Cas 9 is a technology that edit parts of the genome.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
May 11, 2020 09:45 ET (13:45 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Apr 2023 to Apr 2024
